Chaozhong Zou
About Chaozhong Zou
Chaozhong Zou is a Senior Scientist and Group Lead at ATCC, specializing in in vitro cell-based assays for drug toxicity and compound screening. He has extensive experience in developing genetically modified stable cell lines and has worked in various research roles across multiple institutions since 2003.
Work at ATCC
Chaozhong Zou has served as a Senior Scientist and Group Lead at ATCC since 2013. In this role, he specializes in in vitro cell-based assays for drug toxicity and compound screening, employing both 2D and 3D models. He leads initiatives focused on media optimization and technology transfer to improve cell production processes. Zou also engages in the development of genetically modified stable cell lines, including reporter lines, and contributes to customer service by offering expertise in cell production and media optimization.
Education and Expertise
Chaozhong Zou holds a Doctor of Philosophy in Biology from Xiamen University. He also earned a Bachelor's degree in Medicine from Anhui Agricultural University. His educational background supports his expertise in in vitro cell-based assays and the development of genetically modified cell lines. Zou's academic training provides a solid foundation for his research and development efforts in the field of drug toxicity and compound screening.
Background
Before joining ATCC, Chaozhong Zou worked as a Research Scientist and Faculty at Northshore University Healthsystem from 2008 to 2013. Prior to that, he was a Research Associate at Northwestern University, Feinberg School of Medicine, from 2003 to 2008. His experience in these roles contributed to his knowledge and skills in cell-based assays and product development initiatives, particularly in primary cell immortalization.
Achievements
Chaozhong Zou has made significant contributions to the field of drug toxicity and compound screening through his work in developing in vitro cell-based assays. He has led efforts in optimizing media and transferring technology to enhance cell production processes. His focus on the development of genetically modified stable cell lines and primary cell immortalization has further advanced product development initiatives in his field.